Fig. 5
The influence of MRTX1133 on PANC1 splenic tumor growth and metastatic capacity. Treatments started 7 days after tumor cell injection with 10 mg/kg MRTX1133 dose, 5 times per week for 22 days. The mice in the control group were treated with the solvent. Termination of the experiment was 29 days after cell inoculation. (A) Significantly lower spleen weight (**p ≤ 0.01, left) and significantly smaller splenic tumors (*p ≤ 0.05, right) were found in the MRTX1133 treated group compared to untreated animals. (B) Vimentin staining of representative spleen sections with splenic tumor areas of control (left) and MRTX1133 treated animals (right). (C) Significantly smaller metastatic lesions (**p ≤ 0.01, left) and a significantly reduced number of metastatic colonies (**p ≤ 0.01, right) were detected in the livers of MRTX1133 treated animals compared to the controls. (D) Vimentin staining of representative metastatic liver sections of control (left) and MRTX1133 treated animals (right). (E) A significantly lower Ki67 index was detected in the splenic tumor of treated animals compared to the control ones, both in splenic tumor and in liver metastasis. (**p ≤ 0.01,*p ≤ 0.05). (F) Representative images of Ki67 expression. (G) Investigation of apoptotic bodies revealed no significant induction of apoptosis following MRTX1133 treatment. Magnified areas depicted on the bottom are indicated by red boxes. Data represent the mean ± SEM of seven animals. C: control samples, M: MRTX1133 treated specimens.
